The NLRP3 inflammasome, a target for therapy in diverse disease states.
about
The inflammasome: an emerging therapeutic oncotarget for cancer preventionInflammasome as a Therapeutic Target for Cancer Prevention and Treatment.Activation of the NLRP3 inflammasome by intracellular poly I:CInflammasomes in cardiovascular diseases.NLRP3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice via Neuroinflammation.CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1β production.Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein.Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians.Anti-inflammatory interventions-what has worked, not worked, and what may work in the future.The significant role of mast cells in cancer.The NLRP3 inflammasome in health and disease: the good, the bad and the ugly.Sensing damage by the NLRP3 inflammasome.TLR-induced NF-κB activation regulates NLRP3 expression in murine macrophages.Decreased CXCR3 expression in CD4+ T cells exposed to asbestos or derived from asbestos-exposed patients.ASC Pyrin Domain Self-associates and Binds NLRP3 Protein Using Equivalent Binding Interfaces.Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.Activation of inflammasome by attenuated Salmonella typhimurium in bacteria-mediated cancer therapy.Activation of the NLRP3 Inflammasome Is Associated with Valosin-Containing Protein Myopathy.OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes
P2860
Q28076914-E7B626C1-3972-46C4-8896-C173ED8986FCQ33888059-0E1180FA-6249-4D8E-B72D-A1744CF7CE6BQ34421170-9B674115-7541-4DF7-8CCF-CCC5E7F4D562Q35660178-AC369E0B-D622-42C9-8D7F-C43C6737FFD3Q36064487-4F704E13-7008-445E-8FE5-C746DD1E1C93Q36278760-C6C987E2-F6FD-46B5-8624-CD23AE843262Q36451881-2670C1AD-29E9-45FD-AE91-6233CC3F84DAQ37331996-7EE0FA5E-0AA6-4C22-8689-CF84DD241EA8Q37336472-3D4EA4DD-E57B-4096-BCD1-5077FA96B539Q37834484-D9C10E43-22D4-445E-8C41-5778088C72A3Q37901519-790C412C-8620-401B-A207-F89C556C4BCDQ37925073-1FC8E130-A235-4E78-8FBC-37A903CF0C10Q39351865-12242217-0283-4FA4-83EA-3A9B5C6AE353Q39584952-C8480B61-12C8-4247-8112-75BAA926D122Q39586516-358C27F6-0DA7-4BF2-B452-87DC3ECED60EQ40093877-334CEE74-2B6C-4F4D-A5E7-587C612BC816Q40937873-E98E224F-B1D2-41F7-9C06-4E1A47DB3D1BQ46797683-1CA72526-7576-492D-9D17-1548D47336D9Q47644899-AB9898A1-0449-4AC9-933A-73119A6FA3C0Q50980583-A9231F03-C3B3-4040-9682-74C61A2C3091Q54806474-69F82C01-B71A-4120-98D3-202457BD2755
P2860
The NLRP3 inflammasome, a target for therapy in diverse disease states.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en-gb
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@nl
type
label
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en-gb
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@nl
prefLabel
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en-gb
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@nl
P50
P356
P1476
The NLRP3 inflammasome, a target for therapy in diverse disease states.
@en
P2093
Miriam Wittmann
P304
P356
10.1002/EJI.200940162
P407
P577
2010-03-01T00:00:00Z